Get started
Vera Therapeutics, Inc.Vera Therapeutics, Inc.Vera Therapeutics, Inc.

Vera Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VERA chart


Full chart

Key facts today

Wedbush increased the price target for Vera Therapeutics, Inc. (VERA) to $38 from $30, keeping a Neutral rating. Analysts show an average buy rating, with price targets between $25 and $107.
Analyze the impactAnalyze the impact

VERA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪3.04 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.60 USD
Net income (FY)
‪−95.99 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪46.97 M‬
Beta (1Y)
1.90

Employees


Employees (FY)
51
Change (1Y)
+5 +10.87%
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−1.88 M‬ USD

About Vera Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Marshall W. Fordyce
Website
veratx.com
Headquarters
Brisbane
Founded
2016
FIGI
BBG00Q72WYG3
Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

VERA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VERA is 48.31 USD — it has decreased by −2.67% in the past 24 hours. Watch Vera Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vera Therapeutics, Inc. stocks are traded under the ticker VERA.
VERA stock has risen by 17.97% compared to the previous week, the month change is a 23.81% rise, over the last year Vera Therapeutics, Inc. has showed a 328.28% increase.
We've gathered analysts' opinions on Vera Therapeutics, Inc. future price: according to them, VERA price has a max estimate of 107.00 USD and a min estimate of 38.00 USD. Watch VERA chart and read a more detailed Vera Therapeutics, Inc. stock forecast: see what analysts think of Vera Therapeutics, Inc. and suggest that you do with its stocks.
VERA reached its all-time high on Mar 1, 2024 with the price of 50.78 USD, and its all-time low was 5.20 USD and was reached on Jan 6, 2023. View more price dynamics on VERA chart.
See other stocks reaching their highest and lowest prices.
VERA stock is 4.12% volatile and has beta coefficient of 1.90. Track Vera Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Vera Therapeutics, Inc. there?
Today Vera Therapeutics, Inc. has the market capitalization of ‪3.04 B‬, it has increased by 2.14% over the last week.
Yes, you can track Vera Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Vera Therapeutics, Inc. is going to release the next earnings report on Mar 20, 2025. Keep track of upcoming events with our Earnings Calendar.
VERA earnings for the last quarter are −0.85 USD per share, whereas the estimation was −0.64 USD resulting in a −33.33% surprise. The estimated earnings for the next quarter are −0.74 USD per share. See more details about Vera Therapeutics, Inc. earnings.
Vera Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
VERA net income for the last quarter is ‪−46.63 M‬ USD, while the quarter before that showed ‪−33.71 M‬ USD of net income which accounts for −38.34% change. Track more Vera Therapeutics, Inc. financial stats to get the full picture.
No, VERA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 51.00 employees. See our rating of the largest employees — is Vera Therapeutics, Inc. on this list?
Like other stocks, VERA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vera Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vera Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vera Therapeutics, Inc. stock shows the strong buy signal. See more of Vera Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.